Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug

Oruka Therapeutics (NASDAQ:ORKA) shares rose 6.6% after the FDA cleared its Investigational New Drug (IND) application for a Phase 2a trial of ORKA-001, targeting moderate-to-severe psoriasis. This advancement into Phase 2 development is significant as the trial, EVERLAST-A, will evaluate the long-acting anti-IL-23p19 antibody for its potential to offer once-yearly dosing and extended off-treatment remissions, aiming to redefine the standard of care. Stifel reiterated a Buy rating and $47.00 price target, with Phase 1 data expected in September and Phase 2a efficacy results anticipated in the second half of 2026.

Analysis

Oruka Therapeutics (ORKA) has achieved a significant clinical milestone with the U.S. Food and Drug Administration's (FDA) clearance of its Investigational New Drug (IND) application for ORKA-001, triggering a 6.6% rise in its stock. This clearance permits the immediate commencement of the EVERLAST-A Phase 2a trial for its long-acting anti-IL-23p19 antibody in moderate-to-severe psoriasis. The trial's primary endpoint is complete skin clearance (PASI 100) at Week 16, and its design uniquely aims to validate the drug's potential for once-yearly dosing and extended off-treatment remission. An analyst from Stifel reiterated a 'Buy' rating and a $47.00 price target, noting that Phase 2a sites are already actively enrolling patients. While this regulatory progress is a positive de-risking event, key efficacy and response data from this trial are not expected until the second half of 2026. Near-term catalysts include the presentation of interim Phase 1 safety and tolerability data at the European Academy of Dermatology and Venereology Congress in September.

Key Decisions for Investors

• The FDA's IND clearance is a positive development, but investors should recognize that the primary value-inflection point, the Phase 2a efficacy data, is not expected until H2 2026, positioning ORKA as a long-term holding.
• Monitor the upcoming presentation of Phase 1 data in September, as positive safety and tolerability results could provide further validation and potentially sustain momentum ahead of the long wait for Phase 2 results.
• The investment thesis rests on ORKA-001's potential to disrupt the psoriasis market with a once-yearly dosing regimen; therefore, any developments from competitors in the anti-IL-23p19 space should be closely watched.
• Given the stock is still in a clinical stage, investors should consider the inherent binary risk associated with trial outcomes, despite the positive analyst outlook and recent regulatory progress.